Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17859660 | 0.82 | KDM4E (0.72) | KDM4EL3MBTL1TDP1NPC1RAB9A | |
| SCHEMBL17859663 | 0.75 | MAPT (0.73) | KDM4EL3MBTL1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL267882 | 0.73 | KDM4E (0.69) | KDM4EL3MBTL1TDP1NPC1RAB9A | |
| SCHEMBL268802 | 0.72 | KDM4E (0.67) | KDM4EL3MBTL1TDP1NPC1RAB9A | |
| SCHEMBL13462547 | 0.72 | RAB9A (0.70) | NPC1RAB9ASMN1; SMN2HPGDMAPT | |
| SCHEMBL13753809 | 0.70 | NPSR1 (0.56) | KDM4ESMN1; SMN2HPGDKMT2ASMYD3 | |
| SCHEMBL126284 | 0.69 | LOXL2 (0.74) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL12228481 | 0.69 | HDAC1 (0.61) | KDM4ENPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL11216517 | 0.68 | SMYD3 (0.60) | KDM4ENPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL12142424 | 0.68 | HDAC6 (0.59) | KDM4ESMYD3KAT6AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | RNGTT, NSUN3, NSUN2 | KDM4E 1535/4885L3MBTL1 115/4885TDP1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.